Regeneron Pharmaceuticals Inc logo

REGN - Regeneron Pharmaceuticals Inc Share Price

$385.94 0.4  0.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £32.58bn
Enterprise Value £30.91bn
Revenue £5.86bn
Position in Universe 257th / 6410
Bullish
Bearish
Unlock REGN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

REGN Revenue Unlock REGN Revenue

Net Income

REGN Net Income Unlock REGN Revenue

Normalised EPS

REGN Normalised EPS Unlock REGN Revenue

PE Ratio Range

REGN PE Ratio Range Unlock REGN Revenue

Dividend Yield Range

REGN Dividend Yield Range Unlock REGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
REGN EPS Forecasts Unlock REGN Revenue
Profile Summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 11, 1988
Public Since January 1, 1991
No. of Shareholders: n/a
No. of Employees: 7,400
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 109,795,764
Free Float (0.0%)
Eligible for
ISAs
SIPPs
REGN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for REGN
Upcoming Events for REGN
Similar to REGN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.